Mitotic and Gender Parallels in Alzheimer Disease: Therapeutic Opportunities

Author(s): X. Zhu, K. M. Webber, G. Casadesus, A. K. Raina, H. G. Lee, M. Marlatt, A. Hartzler, C. S. Atwood, R. Bowen, G. Perry, M. A. Smith

Journal Name: Current Drug Targets

Volume 5 , Issue 6 , 2004

Become EABM
Become Reviewer
Call for Editor


In this review, we discuss the role of cell cycle dysfunction in the pathogenesis of Alzheimer disease and propose that such mitotic catastrophe, as one of the earliest events in neuronal degeneration, may, in fact, be sufficient to initiate the neurodegenerative cascade. The question as to what molecule initiates cell cycle dysfunction is now beginning to become understood and, in this regard, the gender-predication, age-related penetrance and regional susceptibility of specific neuronal populations led us to consider luteinizing hormone as a key mediator of the abnormal mitotic process. As such, agents targeted toward luteinizing hormone or downstream sequelae may be of great therapeutic value in the treatment of Alzheimer disease.

Keywords: alzheimer disease, amyloid, cell cycle, leuprolide acetate, luteinizing hormone, oxidative stress, tau phosphorylation

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2004
Page: [559 - 563]
Pages: 5
DOI: 10.2174/1389450043345317
Price: $65

Article Metrics

PDF: 2